Your Good Partner in Biology Research

  1. 首頁
  2. 蛋白
  3. 重組蛋白
  4. Recombinant Human Insulin-like growth factor-binding protein 5 (IGFBP5)

Recombinant Human Insulin-like growth factor-binding protein 5 (IGFBP5)

In Stock
  • 中文名稱：
    人IGFBP5重組蛋白
  • 貨號：
    CSB-EP011099HU
  • 規(guī)格：
    ￥1344
  • 圖片：
    • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • 其他：

產(chǎn)品詳情

  • 純度：
    Greater than 85% as determined by SDS-PAGE.
  • 基因名：
    IGFBP5
  • Uniprot No.：
  • 別名：
    IBP-5;IGF-binding protein 5;IGFBP-5
  • 種屬：
    Homo sapiens (Human)
  • 蛋白長度：
    Full Length of Mature Protein
  • 來源：
    E.coli
  • 分子量：
    36.0 kDa
  • 表達區(qū)域：
    21-272aa
  • 氨基酸序列
    LGSFVHCEPCDEKALSMCPPSPLGCELVKEPGCGCCMTCALAEGQSCGVYTERCAQGLRCLPRQDEEKPLHALLHGRGVCLNEKSYREQVKIERDSREHEEPTTSEMAEETYSPKIFRPKHTRISELKAEAVKKDRRKKLTQSKFVGGAENTAHPRIISAPEMRQESEQGPCRRHMEASLQELKASPRMVPRAVYLPNCDRKGFYKRKQCKPSRGRKRGICWCVDKYGMKLPGMEYVDGDFQCHTFDSSNVE
    Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
  • 蛋白標簽：
    N-terminal 10xHis-tagged and C-terminal Myc-tagged
  • 產(chǎn)品提供形式：
    Liquid or Lyophilized powder
    Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
  • 緩沖液：
    If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
  • 復溶：
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
  • 儲存條件：
    Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
  • 保質(zhì)期：
    The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
    Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
  • 貨期：
    3-7 business days
  • 注意事項：
    Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
  • Datasheet & COA：
    Please contact us to get it.

產(chǎn)品評價

靶點詳情

  • 功能：
    IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
  • 基因功能參考文獻：
    1. Data suggest that IGFBP5 nuclear import is mediated by KPNA5/KPNB1 complex; nuclear localization sequence of IGFBP5 is critical domain in this nuclear translocation. (IGFBP5 = insulin-like growth factor binding protein-5; KPNA5 = karyopherin subunit alpha-5; KPNB1 = karyopherin subunit beta-1/importin-beta) PMID: 28835592
    2. These results suggest that the C-terminus of IGFBP-5 exerts anti-cancer activity by inhibiting angiogenesis via regulation of the Akt/ERK and NF-kB-VEGF/MMP-9 signaling pathway. PMID: 28008951
    3. AMP-IBP5 markedly enhanced keratinocyte migration and proliferation. AMP-IBP5-induced keratinocyte activation was mediated by Mrg X1-X4 receptors with MAPK and NF-kappaB pathways. PMID: 28554590
    4. Factor Xa induced endothelial cell senescence through IGFBP-5. PMID: 27752126
    5. The findings suggest that miR-140 suppresses colorectal cancer progression and metastasis, possibly through downregulating ADAMTS5 and IGFBP5. PMID: 27906093
    6. MiR-137 inhibited cell proliferation and migration of vascular smooth muscle cells via targeting IGFBP-5 and modulating the mTOR/STAT3 signaling. PMID: 29016699
    7. dysregulation of DNMT3A and IGFBP5 is relevant to preeclampsia. Thus, we propose that DNMT3A and IGFBP5 can serve as potential markers and targets for the clinical diagnosis and therapy of preeclampsia. PMID: 28049695
    8. IGFBP5 promoter and exon-I methylation did not have any differences between tumor and adjacent tissues so that IGFBP5 methylation did not change IGFBP5 gene regulation in breast cancer. PMID: 27612043
    9. IGFBP5 promoted osteogenic differentiation potentials of periodontal ligament stem cells and Wharton's jelly umbilical cord stem cells via the JNK and MEK/Erk signalling pathways. PMID: 27484838
    10. Data demonstrate that dysregulation of miR-143-3p:Igfbp5 interactions in satellite cells with age may be responsible for age-related changes in satellite cell function. PMID: 26762731
    11. Results shed light on the mechanism of IGFBP5 as a potential tumor-suppressor in melanoma progression. PMID: 26010068
    12. data provide further insights into the role of cellular compartmentalization in IGFBP-5-induced fibrosis PMID: 26103640
    13. Demethylation of IGFBP5 by Histone Demethylase KDM6B Promotes Mesenchymal Stem Cell-Mediated Periodontal Tissue Regeneration by Enhancing Osteogenic Differentiation and Anti-Inflammation Potentials. PMID: 25827480
    14. rs4442975 at 2q35 flanks a transcriptional enhancer that physically interacts with the promoter of IGFBP5. Evidence suggests that the g-allele confers increased breast cancer susceptibility through relative downregulation of IGFBP5. PMID: 25248036
    15. IGFBP5 mRNA expression is a good indicator in clinical outcome of breast cancer patients. PMID: 25422220
    16. miR-204-5p suppresses IGFBP5 expression by direct binding to the 3' untranslated region. PMID: 25603050
    17. IGFBP-5 may be a negative modulator of RASSF1C/ PIWIL1 growth-promoting activities. PMID: 25007054
    18. IGFBP-5 induces its pro-fibrotic effects, at least in part, via DOK5. IGFBP-5 and DOK5 are both increased in systemic sclerosis fibroblasts and tissues and may thus be acting in concert to promote fibrosis. PMID: 24551065
    19. IGFBP-5 is important in maintaining epithelial-mesenchymal boundaries and thus may limit metastasis and fibrosis by inducing an orderly repair mechanism, very distinct from the fibrotic disruption induced by TGFbeta1. PMID: 24120850
    20. Serum IGFBP-5 concentrations were lower in Crohn's disease patients compared to healthy controls regardless of disease activity or the presence of stricture formation. PMID: 24379630
    21. IGFBP-5 modulates the efficiency of estrogen-triggered activation of the Akt/PKB signaling pathway which has been associated with growth factor/ ERalpha cross-talks. PMID: 23499909
    22. IGFBP-5 overexpression is a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. PMID: 23539739
    23. IGFBP5 domains modulate tumorigenicity and metastasis of human osteosarcoma in different ways PMID: 23665505
    24. Data suggest that insulin-like growth factor-binding protein 5 (IGFBP5) regulation by calcium-dependent chloride channel DOG1. PMID: 23576565
    25. The IGFBP5 enhanced adhesion, it inhibited cell migration, although this was not evident using the truncated C-terminal mutant, suggesting that effects of IGFBP5 on adhesion and migration involve different mechanisms. PMID: 22328518
    26. c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling PMID: 22252554
    27. This study demonistrated that IGFBP5 was significantly decreased in skeletal muscel in patient with amyotrophic lateral sclerosis. PMID: 22246875
    28. Data revealed a strong induction of several genes encoding components of the extracellular matrix, such as collagens, COMP, IGFBP5 and biglycan. PMID: 21029365
    29. Insulin-like growth factor binding protein 5 is a novel marker that has an important role in the pathogenesis of osteosarcoma. The loss of insulin-like growth factor binding protein 5 function may contribute to metastasis in osteosarcoma. PMID: 21460855
    30. The IGFBP5 polymorphism is functional and may potentially be a biomarker for susceptibility to late-stage risk of squamous cell carcinoma of the head and neck. PMID: 20949447
    31. results suggest that PGE(2) may play an important role in controlling cellular senescence of HDFs through the regulation of IGFBP5 and therefore may contribute to inflammatory disorders associated with aging PMID: 21191810
    32. Decreased Cav-1 expression in fibrotic diseases likely leads to increased deposition of IGFBP-5 in the extracellular matrix. PMID: 20345844
    33. the L-domain of IGFBP-5 is a novel TNFR1 ligand that functions as a competitive TNF-alpha inhibitor. PMID: 21256825
    34. IGFBP-5 has an effect on human hair shape. PMID: 20944648
    35. Data indicate that retinal astrocytes enhance the proliferation of cone-like retinoblastoma cells by deploying IGFBP5, a factor that also provides trophic support to the tumor cells' non-neoplastic counterparts. PMID: 20508032
    36. Data show that IGFBP5 expression is down-regulated during 4HPR-induced neuronal differentiation of human RPE cells through a MAPK signal transduction pathway involving C/EBPbeta. PMID: 20583135
    37. insulin-like growth factor binding protein 5 is a modulator of tamoxifen resistance in breast cancer PMID: 20354179
    38. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. PMID: 19948051
    39. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). PMID: 11821401
    40. role in stimulating growth and IGF-I secretion in intestinal smooth muscle by ras-dependent activation of MAP kinase signaling pathways PMID: 11923300
    41. c-Myb and B-Myb transactivate the IGFBP-5 promoter through binding-dependent and -independent mechanisms. PMID: 11973331
    42. cDNA probes were used to analyze the gene expression of IGFBP-5 in luteinized granulosa cells from different-sized follicles after ovarian hyperstimulation. Transcript levels increased with increasing follicular fluid (FF) volume PMID: 12005306
    43. IGFBP-5 is a potent growth inhibitor and proapoptotic agent in human breast cancer cells via modulation of cell cycle regulation and apoptotic mediators PMID: 12777377
    44. Fibronectin and IGFBP-5 bind to each other, and this binding negatively regulates the ligand-dependent action of IGFBP-5 by triggering IGFBP-5 proteolysis. PMID: 14645245
    45. The IGFBP-5 C-domain is necessary and sufficient for its nuclear localization, and residues K206, K208, K217, and K218 are particularly critical. The IGFBP-5 N-domain contains a putative transactivation domain. PMID: 15001525
    46. exogenous IGFBP-5 increases apoptosis by binding to and inhibiting the activities of insulin-like growth factors PMID: 15155755
    47. Understanding the mechanism of how cleavage of IGFBP-5 by this protease (IGFBPase) alters its activity will help to further our understanding of the biologic actions of the IGFs PMID: 15534875
    48. Inhibition of expression of IGFBP-5 by micro and small interfering RNA has marked effect on neuroblastoma cell proliferation, apoptosis, and differentiation PMID: 15618969
    49. IGFBP-5 has a role in growth and differentiation of neuroblastoma cells PMID: 15650232
    50. Activation by C/EBP alpha and beta did not depend on their binding to the C/EBP site, since they still activated IGFBP-5 promoter. PMID: 15777798

    顯示更多

    收起更多

  • 亞細胞定位：
    Secreted.
  • 組織特異性：
    Osteosarcoma, and at lower levels in liver, kidney and brain.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 5474

    OMIM: 146734

    KEGG: hsa:3488

    STRING: 9606.ENSP00000233813

    UniGene: Hs.607212